As the window closes on Heidi Overton’s FDA nomination, she joins an unfortunate club

When Donald Trump announced in August that he wanted Dr. Heidi Overton, a White House health aide, to lead the Food and Drug Administration, there was some reporting that she wasn’t necessarily the president’s first choice. She received the nomination anyway, in part because she was willing to work within the hyperpoliticized climate, and in part because the White House was satisfied that she would go along with Trump’s plans.

We now know she won’t get that chance. MS NOW reported:

The Trump administration withdrew its nomination of White House health aide Heidi Overton to lead the Food and Drug Administration Tuesday amid opposition from Senate Republicans, a White House official confirmed to MS NOW.

The official did not provide a reason for the withdrawal, but the move comes after Sen. Bill Cassidy, R-La., a physician and chair of the Senate Health Education, Labor and Pensions Committee, said last week that he and other GOP committee members were “undecided” about Overton.

Axios first reported on the withdrawal, which came less than a day before the Senate committee was scheduled to vote on advancing Overton’s nomination.

There are still some lingering questions as to why, exactly, Trump’s FDA pick was pulled, but while the public waits for those answers, it’s worth appreciating an underappreciated dynamic: The White House is so bad at choosing nominees, even Senate Republicans won’t confirm some of them.

The list of Trump’s failed second-term nominees has quietly become rather long. It includes a variety of notable figures, tapped for positions large and small, including Matt Gaetz, Dave Weldon, Ed Martin, Chad Chronister, Kathleen Sgamma, E.J. Antoni, Paul Ingrassia, Jeremy Carl, Donald Korb, Scott Socha, Sean Plankey, Amer Ghalib, Bryce McFerran and Casey Means, among others.

Over the last 22 months or so, the White House has left little doubt that it would much prefer that the Republican-led Senate simply serve as a rubber stamp for the president’s choices, regardless of merit or qualifications. And looking at Trump’s Cabinet, it’s clear that GOP senators have been willing to go along with too many nominees who had no business taking office.

But as Overton exits the stage, the president and his team were reminded once again that there are some depths to which even Senate Republicans don’t want to sink.

This post updates our related earlier coverage.

The post As the window closes on Heidi Overton’s FDA nomination, she joins an unfortunate club appeared first on MS NOW.

Source Author
Author: Source Author

From MS Now.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *